Heart Failure & Cardiomyopathy
Contact Information
Location
Boswell Building
300 Pasteur Drive
A 260 (2nd floor)
Stanford, CA
Appointments
Phone: (650) 723-5468
Fax: (650) 725-1927
Clinic Hours
Monday - Friday
8:30am - 5:00pm
OVERVIEW
Stanford has the accumulated wisdom of many years of research and continues to develop the latest advancements in the diagnosis and treatment of congestive heart failure and cardiomyopathy.
For patients, this translates into a multidisciplinary program that includes cardiologists specializing in heart failure management, cardiovascular surgeons, electrophysiologists, radiologists and molecular biologists.
Specialists meet weekly to discuss the best possible treatment plan for each patient. A support team of nurse specialists, a financial counselor and social workers focuses its attention on the educational, financial and psychosocial needs of our patients.
Our areas of treatment expertise include:
• Left ventricular assist device (LVAD) insertion for both short term and long term use
• Inherited cardiovascular disease
• Cardio-Oncology (heart failure associated with chemotherapy/cancer)
• Medication management
• Radiation induced heart disease
• Pacemakers and Implantable cardioverter defibrillators
• Cardiac resynchronization therapy
• Myotomy, Myectomy and Septal Ablation for Hypertophic Cardiomyopathy
• Left ventricular remodeling: surgical ventricular restoration
Heart failure diagnostic services include ECG, cardiac catheterization, myocardial biopsy to exclude myocarditis and infiltrative diseases, and risk/survival assessment.
SERVICE HIGHLIGHT: LVAD PROGRAM
Left ventricular assist device (LVAD) therapy has become more promising due to recent data that suggests improved survival and quality of life in patients with end stage heart failure. Our group is expanding the use of this new technology beyond patients who are waiting for transplant (‘bridge to transplant’) to patients who do not qualify for transplant but have an unacceptable quality of life on medical therapy (‘destination therapy’). At Stanford, we have the newest devices available, including the HeartMate II and HeartWare devices, in order to provide the best care for our patients.
CUTTING-EDGE RESEARCH
The heart failure group has a long tradition of internationally recognized research, beginning with the pivotal trials of beta blocker therapy conducted by the director of the cardiomyopathy center, Michael B Fowler. Current research interests include the role of insulin resistance in the development and treatment of cardiomyopathy (Fowler, Witteles, Banerjee), new approaches to the diagnosis and treatment of cardiomyopathy using genetic testing (Ashley), novel therapies for amyloid cardiomyopathy (Witteles), cardio-oncology (Witteles), and heart failure improvement measures (Banerjee, Fowler).